Genomics 10x Guides Q4 and Fiscal Year Higher Than Consensus (TXG:NASDAQ)


3rd to 4th quarter symbol. Wooden cubes turned and words changed

Dmitri Dzemidovich

  • 10x Genomics (NASDAQ:TXG) wait Q4 revenue of ~$165M, representing 9% Q/Q growth and 10% YoY decline; the number remains above the consensus estimates of 153.51 million dollars.
  • The highest year-on-year growth is estimated to come from the services segment, while instruments



Source link

  • Related Posts

    Progyny’s premarket value rises 5.8% on improved 4Q forecast By Investing.com

    Investing.com — Progyny (NASDAQ: ), a company specializing in the management of fertility benefits, reported a 5.8% increase in its premarket value after showing that the results of the fourth…

    Regeneron Announces IPR Charges

    Regeneron Announces IPR Charges Source link

    Leave a Reply

    Your email address will not be published. Required fields are marked *